Yassin Taher/ LinkedIn
May 29, 2026, 09:53
Yassin Taher: Recognizing Clonal Eosinophilic Disorders in Pediatric Hypereosinophilic Syndrome
Yassin Taher, Pediatric Oncology Consultant at Children’s Cancer Hospital, shared a post on LinkedIn:
“Pediatric Hypereosinophilic Syndrome (HES) can mimic infection, autoimmune disease, lymphoma, or primary immunologic disorders.
I created this high-yield visual summary to simplify:
- Classification
- Diagnostic approach
- Molecular testing
- Organ involvement
- Modern targeted therapies
Key takeaway: Always evaluate persistent eosinophilia with evidence of organ dysfunction for possible clonal eosinophilic disorders, particularly FIP1L1–PDGFRA–associated disease due to its dramatic response to imatinib.”
Stay updated with Hemostasis Today.
-
May 29, 2026, 09:52Sergio Emanuel Kaiser: Ruvonoflast and a New Anti-Inflammatory Strategy for Residual Cardiovascular Risk
-
May 29, 2026, 09:50Maria Symiakaki: Advancing Cardiovascular Prevention at the 2026 Congress of the European Atherosclerosis Society
-
May 29, 2026, 09:37Katie Baca-Motes: What Can Menstrual Cycle Physiology Tell Us About Health Beyond Reproduction?
-
May 29, 2026, 09:35Torben Boelk: Bringing Plasma Donation to the Heart of Leipzig
-
May 29, 2026, 04:37Josefin Ahnström: How Andexanet Alfa Impacts TFPIα Function
-
May 29, 2026, 03:19Building Safer Systems for Anticoagulation Management – ISTH
-
May 29, 2026, 03:07Early Diagnosis Can Change the Lives of Women With Haemophilia – EHC
-
May 29, 2026, 02:41Ifeanyichukwu Ifechidere: The Biggest DOAC Myth in Coagulation – ‘No Monitoring Required’
-
May 29, 2026, 02:35Mariam Swidan: Why Is LDH the ‘Tattletale’ of the Lab?